Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2003

View Archived Issues

Milnacipran reduces pain in depressed and nondepressed FMS patients

Novacea licenses North American rights to AQ4N

Oxigene expands ophthalmology R&D program

Combidex improves the accuracy of MRI in the diagnosis of metastatic cancer

DB-289 safe and effective in patients with first-stage sleeping sickness

Clinical trials confirm good safety profile of yellow fever vaccine; BLA filed

Phase II results for Itax confirm earlier safety and efficacy findings

Ketek launched in Japan

Generex and Acertus to develop oral recombinant human growth hormone

Canadian notice of noncompliance for Circadin

Finacea approved in E.U. as topical treatment of papulopustular rosacea

Targent acquires dibromodulcitol

CSL to acquire Aventis Behring

Chugai launches Pegasys in Japan

Japanese rights to bevacizumab and pertuzumab licensed to Chugai

Disappointing results for HuMax-CD4 in phase IIb psoriasis trial

Start of phase I safety study of Genz-29155 announced by Genzyme

Niaspan and Advicor filed for marketing approval in Canada

Independent committee recommends early end to phase III Velcade trial

Enrollment completed in phase II study of ThGRF in HIV-related lipodystrophy

Immunosuppressant series patented by Sankyo

Valera files Vantas NDA

Beta-lactamase inhibitors prepared by Wyeth team

New combinations for the treatment of cardiac arrhythmias

Merck scientists synthesize new chemokine receptor modulators

Caspase inhibitors designed by Korean researchers

Neurogen identifies imidazole-based GABA-A receptor ligands

New findings on structure and function of prostate-specific membrane antigen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...